EUCTR2009-014373-41-FR进行中（未招募）1 期
A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR) - CHOICES-CHlOroquine and Imatinib Combination to Eliminate Stem cells
HS Greater Glasgow and Clyde0 个研究点开始时间: 2013年4月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients aged = 18 years old.
- •2.Ability to provide written informed consent prior to participation in the study and any related procedures being performed.
- •3.Patient must have a fusion gene that can be monitored by Q-PCR.
- •4.CML CP patients who have been treated with and tolerated Imatinib for >12 months have achieved at least MCyR and continue to be BCR/ABL+ by Q-PCR. Patients should be receiving a stable dose of Imatinib for 6 months prior to study entry.
- •5.Patients must meet the following laboratory criteria:
- •ANC and platelets need to be stable and in the normal range for =2 months with ANC >1.5 and platelets > 100 for =2 months
- •Serum albumin >3g/dl
- •AST and/or ALT =2.5 x Upper limit of normal (ULN)
- •Serum bilirubin =1.5 x ULN
- •Serum creatinine =1.5 x ULN or 24-hour creatinine clearance =50 ml/min
- •Serum potassium =LLN with or without replacement therapy
- •6.ECOG Performance Status of =2.
- •7.Without any legal protection measure.
- •8.Having a health coverage.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1.Patient who have been treated with Imatinib <12 months or patients who have changed dose in previous 6 months.
- •2.Impaired cardiac function including any one of the following:
- •Screening ECG with a QTc >450 msec
- •Patients with congenital long QT syndrome
- •History or presence of sustained ventricular tachycardia
- •Any history of ventricular fibrillation or torsades de pointes
- •Congestive heart failure (NY Heart Association class III or IV)
- •Uncontrolled hypertension
- •3.Patients with severe GI disorder, uncontrolled epilepsy, known G6PD deficiency, known porphyria, moderate or severe psoriasis, known myasthenia gravis or other concurrent severe and/or uncontrolled medical conditions.
- •4.Patients who have received chemotherapy, any investigational drug or undergone major surgery <4 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
- •5.Concomitant use of any other anti-cancer therapy or radiation therapy.
- •6.Patients who have a pre-exisiting maculopathy of the eye.
- •7.Female patients who are pregnant or breast feeding or patients of reproductive potential not willing to use a double method of contraception including a barrier method (i.e. condom) during the study and 3 months after the end of treatment. (Patients should continue with standard contraceptive precautions beyond the study period as per Imatinib).
- •8.Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of oral HCQ.
- •9.Male patients whose sexual partners are WOCBP not willing to use a double method of contraception including condom during the study and 3 months after the end of treatment on study. (Patients should continue with standard contraceptive precautions beyond the study period as per Imatinib).
- •10.Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.
- •11.No affiliation to the French social health insurance system.
研究者
相似试验
进行中（未招募）
1 期
A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and IM for patients with Chronic Myeloid Leukaemia (CML) in Major Cytogenetic Response (MCyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR) - CHOICES-CHlOroquine and Imatinib Combination to Eliminate Stem cellsChronic Myeloid LeukaemiaMedDRA version: 15.0Level: PTClassification code 10009013Term: Chronic myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014373-41-DEClinical Trial Center Aachen76
已完成
2 期
Imatinib (IM) versus hydroxychloroquine (HCQ) and IM for patients with chronic myeloid leukaemia (CML) in cytogenetic response (CyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR)Chronic myeloid leukaemiaMyeloid leukaemiaCancerISRCTN61568166HS Greater Glasgow and Clyde (UK)66
进行中（未招募）
1 期
A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR) - CHOICES-CHlOroquine and Imatinib Combination to Eliminate Stem cellsChronic Myeloid LeukaemiaMedDRA version: 14.0 Level: PT Classification code 10009013 Term: Chronic myeloid leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014373-41-GBHS Greater Glasgow and Clyde62
进行中（未招募）
1 期
A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 20.0 Level: LLT Classification code 10062427 Term: Gastrointestinal stromal tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10051066 Term: Gastrointestinal stromal tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001298-42-GBEuropean Organisation for Research and Treatment of Cancer76
进行中（未招募）
不适用
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 18.0Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001298-42-ESEuropean Organisation for Research and Treatment of Cancer240